Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05845489 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Mar 31, 2030 to Dec 31, 2028 Enrollment target: 9930 to 11086 · Study sites: 1 to 61 · Completion date: Mar 31, 2030 to Dec 31, 2031 · 4 morev3 Show 7 more changesShow less
    • Enrollment target: 9930 to 11086
    • Study sites: 1 to 61
    • Completion date: Mar 31, 2030 to Dec 31, 2031
    • Start date: Mar 9, 2023 to Mar 22, 2023
    • Secondary endpoints: 12 to 11
    • Collaborators: 6 to 7
    • Eligibility criteria expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  2. Collaborators expanded, about 24 wordsv2 See this version in full on ClinicalTrials.gov ↗
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The investigators will evaluate the efficacy and safety of clopidogrel for primary prevention in patients diagnosed with coronary atherosclerosis on imaging that did not require revascularization therapy. The trial will test the hypothesis that clopidogrel is beneficial in preventing major adverse cardiovascular and cerebrovascular events (MACCE) in patients with subclinical coronary atherosclerosis identified on imaging.
Trial Details
NCT Number NCT05845489
Lead Sponsor Seoul National University Hospital
Collaborators: Samjin Pharmaceutical Co., Ltd., CKD Pharmaceutical Limited, Hanmi Pharmaceutical co., ltd., Yuhan Pharmaceutical Company, Daewoong Pharmaceutical Co. LTD., Dong-A ST Co., Ltd., IlDong Pharmaceutical Co Ltd
Conditions Coronary Artery Disease
Enrollment 11,086 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov